Multiple sclerosis (MS) is condition in which the
immune system attacks myelin sheath, which may eventually damage the neurons and
leave scar tissue, relapsing multiple sclerosis is a type of sclerosis in which
there is flare up following remission, which means during the relapsing phase,
the symptoms of MS will partially or completely go away.
daclizumab is a type of Interleukin 2 receptor (IL2R) antagonist
which is used in the treatment of MS. (Interleukin is a type of Cytokine which binds
with IL2R to generate immune responses, a type cell signalling) daclizumab was administered as an injection under
brand ZINBRYTA, which was first approved by FDA on 27th May 2016,
however recently the Pharmacovigilance Risk Assessment committee (PRAC), a part
of European Medical Agency recommended restrictions on using daclizumab, due to
safety issues associated with serious liver damage (as reported in a clinical trial
where 1.7 % subjects developed serious liver reaction, a suspected unexpected
serious adverse reaction (SUSAR) when administered with daclizumab).
We at Think I are committed to provide robust
pharmacovigilance solutions. We use cloud based technology which
are not only cost effective and user friendly but also fully validated for
quick, easy import, entry and electronic submissions of adverse event.
For more details, contact us at +91 9560102587, +91 9810068241 or
email us at medical@thinki.in or simply visit www.thinki.in
This comment has been removed by a blog administrator.
ReplyDelete